BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...bodies next year to assess a path forward. Boehringer, Epizyme terminate epigenetic dealBoehringer Ingelheim GmbH and Epizyme Inc....
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...Rock Ventures, where he was an entrepreneur in residence, and previously was SVP of research at Epizyme Inc....
BioCentury | Aug 27, 2020
Distillery Therapeutics

Promoting expression of immune targets IFI16 and NLRC5 for melanoma

...in combination with anti-PD-1 therapies in patients who have failed to respond to immune checkpoint therapy.Epizyme Inc....
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

...to Tazverik tazemetostat from Epizyme Inc. (NASDAQ:EPZM) to treat third-line relapsed or refractory follicular lymphoma. An Epizyme...
...Programmed cell death 1 BioCentury Staff Crysvita (burosumab-twza , KRN23, UX023) Tazverik, tazemetostat (E7438, EPZ-6438) Plenity, Gelesis100 (attiva) Ultragenyx Pharmaceutical Inc. Epizyme Inc. Sarepta...
BioCentury | Mar 21, 2020
Management Tracks

Kutok joins Epizyme as CSO; plus ADC Therapeutics, Emulate, E-Scape, MiMedx and RubrYc

...the wake of its first FDA approval, for Tazverik tazemetostat to treat epitheliod sarcoma (see "Epizyme...
...created position. Baliga was VP of discovery biology at IGM Biosciences Inc. (NASDAQ:IGMS). Robin Sawka, BioCentury Staff Epizyme Inc. ADC...
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...had over 3,000 employees. Mott is chairman of Adaptimmune Therapeutics plc (NASDAQ:ADAP), Ardelyx Inc. (NASDAQ:ARDX), Epizyme Inc....
BioCentury | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

...first approved drug in the indication. A few days later, it approved Tazverik tazemetostat from Epizyme Inc....
BioCentury | Jan 23, 2020
Company News

Thirteen years from founding, Epizyme scores first FDA approval

...Despite multiple setbacks over the years, Epizyme now has an approved drug on which to hang...
...month, the agency’s Oncologic Drugs Advisory Committee voted 11-0 to recommend approval of the drug. Epizyme Inc....
...in U.S. clinical trials (see “FDA Places Hold on Epizyme’s Tazemetostat” ). In August 2018, Epizyme...
BioCentury | Dec 18, 2019
Company News

Dec. 18 Company Quick Takes: FDA approves enfortumab vedotin; plus ODAC roundup, Illumina-PacBio, Benlysta, Ultragenyx, Syros-GBT, Xtandi

...cancer; and 11-0 for tazemetostat from Epizyme Inc. (NASDAQ:EPZM) for epithelioid sarcoma. Shortly after the vote, Epizyme...
BioCentury | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

...applications for luspatercept from Celgene Corp. (NASDAQ:CELG) to treat myelodysplastic syndromes and for tazemetostat from Epizyme Inc....
Items per page:
1 - 10 of 245
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...bodies next year to assess a path forward. Boehringer, Epizyme terminate epigenetic dealBoehringer Ingelheim GmbH and Epizyme Inc....
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...Rock Ventures, where he was an entrepreneur in residence, and previously was SVP of research at Epizyme Inc....
BioCentury | Aug 27, 2020
Distillery Therapeutics

Promoting expression of immune targets IFI16 and NLRC5 for melanoma

...in combination with anti-PD-1 therapies in patients who have failed to respond to immune checkpoint therapy.Epizyme Inc....
BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

...to Tazverik tazemetostat from Epizyme Inc. (NASDAQ:EPZM) to treat third-line relapsed or refractory follicular lymphoma. An Epizyme...
...Programmed cell death 1 BioCentury Staff Crysvita (burosumab-twza , KRN23, UX023) Tazverik, tazemetostat (E7438, EPZ-6438) Plenity, Gelesis100 (attiva) Ultragenyx Pharmaceutical Inc. Epizyme Inc. Sarepta...
BioCentury | Mar 21, 2020
Management Tracks

Kutok joins Epizyme as CSO; plus ADC Therapeutics, Emulate, E-Scape, MiMedx and RubrYc

...the wake of its first FDA approval, for Tazverik tazemetostat to treat epitheliod sarcoma (see "Epizyme...
...created position. Baliga was VP of discovery biology at IGM Biosciences Inc. (NASDAQ:IGMS). Robin Sawka, BioCentury Staff Epizyme Inc. ADC...
BioCentury | Mar 5, 2020
Management Tracks

Mott retires from NEA

...had over 3,000 employees. Mott is chairman of Adaptimmune Therapeutics plc (NASDAQ:ADAP), Ardelyx Inc. (NASDAQ:ARDX), Epizyme Inc....
BioCentury | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

...first approved drug in the indication. A few days later, it approved Tazverik tazemetostat from Epizyme Inc....
BioCentury | Jan 23, 2020
Company News

Thirteen years from founding, Epizyme scores first FDA approval

...Despite multiple setbacks over the years, Epizyme now has an approved drug on which to hang...
...month, the agency’s Oncologic Drugs Advisory Committee voted 11-0 to recommend approval of the drug. Epizyme Inc....
...in U.S. clinical trials (see “FDA Places Hold on Epizyme’s Tazemetostat” ). In August 2018, Epizyme...
BioCentury | Dec 18, 2019
Company News

Dec. 18 Company Quick Takes: FDA approves enfortumab vedotin; plus ODAC roundup, Illumina-PacBio, Benlysta, Ultragenyx, Syros-GBT, Xtandi

...cancer; and 11-0 for tazemetostat from Epizyme Inc. (NASDAQ:EPZM) for epithelioid sarcoma. Shortly after the vote, Epizyme...
BioCentury | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

...applications for luspatercept from Celgene Corp. (NASDAQ:CELG) to treat myelodysplastic syndromes and for tazemetostat from Epizyme Inc....
Items per page:
1 - 10 of 245